Related Experiment Videos
Summary
Chemotherapy for acute myelogenous leukemia during pregnancy is rare. A 29-week premature infant, whose mother received treatment, showed low growth but normal development at 14 months.
Area of Science:
- Hematology
- Obstetrics
- Neonatology
Background:
- Limited data exists on treating acute myelogenous leukemia (AML) during pregnancy with novel chemotherapeutic agents.
- Pregnancy complicates AML management due to potential risks to both mother and fetus.
Observation:
- A case report details a pregnant patient diagnosed with AML and treated starting at the 24th week of gestation.
- The infant was delivered prematurely at 29 weeks gestation.
Findings:
- At 14 months post-delivery, the infant exhibited below-average height and weight.
- Crucially, the infant maintained a normal head circumference and demonstrated typical developmental milestones.
Implications:
- This case highlights the possibility of managing AML during pregnancy with newer agents, despite prematurity.
- Further research is needed to establish long-term outcomes and safety profiles for infants exposed to chemotherapy in utero.
- This case contributes to the limited understanding of neonatal outcomes following maternal AML treatment during gestation.